

PHARMA DEKO PLC

..... Providing Healthy Solutions

PHARMA-DEKO PLC

UNAUDITED FINANCIAL STATEMENTS FOR HALF
YEAR ENDED 30TH JUNE 2022

Prepared in accordance with IFRS & IAS 34

TABLE OF CONTENT


Page 2	TABLE OF CONTENT
Page 3	FINANCIAL HIGHLIGHTS
Page 4	STATEMENT OF FINANCIAL POSITION
Page 5	STATEMENT OF COMPREHENSIVE INCOME
Page 6	STATEMENTS OF CHANGES IN EQUITY
Page 7	STATEMENT OF CASH FLOW.
Page 8-19	NOTES TO THE FINANCIAL STATEMENT

Financial Highlights of Pharma-Deko PLC Operations Ended June 2022:

Half Year Ended June 30th 2022

	Description	As At 30th June' 2022		As At 30th June'2021		Diff	
		N'000	% Revenue	N'000	% Revenue	N'000	%
1	Revenue	252,810	100%	311,733	100%	(58,923)	-19%
2	Cost of sales	(207,180)	-82%	(216,837)	-70%	9,657	4%
3	Loss before taxation	(48,990)	-19%	(8,269)	-3%	(40,721)	-492%
4	Taxation	0	0%	0	0%	0	0%
5	Loss after taxation	(48,990)	-19%	(8,269)	-3%	(40,721)	-492%
6	Issued Share Capital	108,466		108,466		0	0%
7	Total Equity	1,258,855		977,998		280,857	29%
8	Total Non Current Assets	2,022,225		1,643,387		378,838	23%
9	Total Current Assets	239,838		303,804		(63,966)	-21%
10	Total Assets	2,262,063		1,947,191		314,872	16%
11	Total Non Current Liabilities	61,556		18,071		43,485	241%
12	Total Current Liabilities	941,652		951,122		(9,470)	-1%
13	Total Equity and Liabilities	2,262,063		1,947,191		314,872	16%

The financial statements and accompanying notes were approved by Board of Directors on and signed on its behalf by:



G.A. Alegieuro - DIRECTOR
(FRC/2014/ICAN/00000007613)


Funmilayo Adedeji - CHIEF ACCOUNTANT
(FRC/2020/ICAN/00000022389)

Statements of Financial Position As At 30 June, 2022

S/N	STATEMENT OF FINANCIAL POSITION		Unaudited AS AT June'2022	Audited AS AT Dec.'2021
	ASSET	NOTE	N''000	N''000
1	PROPERTY, PLANT AND EQUIPMENT	6	2,022,225	2,056,472
2	Intangible assets	6.2	-	
			2,022,225	2,056,472
	CURRENT ASSETS			
3	Stocks(Inventories)	7	152,417	182,383
4	Trade Receivables	8	46,747	11,690
5	Other Receivables and prepayments	9	29,017	46,022
6	Cash and bank balances	10	11,657	38,754
			239,838	278,849
	Total Assets		2,262,063	2,335,321
	Equity and liabilities			
7	Share capital	17	108,466	108,466
8	Share premium	18	380,009	380,009
9	Revaluation reserve	19	1,756,588	1,756,588
10	Retained (loss)/earnings	20	(986,208)	(937,218)
	Total Equity		1,258,855	1,307,845
11	Deferred Tax Liability	16	61,556	61,556
	Total Non Current Liabilities		61,556	61,556
12	Employee Benefits	11	197,577	197,827
13	Loans and Borrowings	10.2	35,000	13,000
14	Trade Payables	12	13,509	14,584
15	Other Payables	13	570,830	615,773
16	Tax Payable	15	124,736	124,736
17	Total Current Liabilities		941,652	965,920
18	Total Liabilities		1,003,208	1,027,476
19	Total Equity and Liabilities		2,262,063	2,335,321

The financial statements and accompanying notes were approved by Board of Directors on and signed on its behalf by:


G.A. Alegieuno - DIRECTOR
 (FRC/2014/ICAN/00000007613)



Funmilayo Adedeji - CHIEF ACCOUNTANT
 (FRC/2020/ICAN/00000022389)


STATEMENT OF COMPREHENSIVE INCOME JANUARY – JUNE 2022:

UNAUDITED ACTUAL Q2 ENDED JUNE 2022 COMPARISM						
		3 months	3 months	6 months	6 months	12 months
DESCRIPTION	Note	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-June 2021	Jan-Dec 2021
		N'000	N'000	N'000	N'000	N'000
Turnover	4	100,420	161,243	252,810	311,733	503,548
Cost of sales		(86,033)	(105,888)	(207,180)	(216,837)	(410,193)
Gross Margin		14,387	55,355	45,630	94,896	93,355
Other operating Income	5.2	25,238	851	25,970	6,260	61,438
Other operating gains (losses)		-	-	-	-	-
		39,625	56,206	71,600	101,156	154,793
Selling and distribution expenses		(6,407)	(12,252)	(22,170)	(21,909)	(22,092)
Administration expenses		(36,510)	(45,255)	(93,510)	(86,541)	(198,357)
Operating (Loss)/profit	5.1	(3,292)	(1,301)	(44,080)	(7,294)	(65,656)
Finance cost		(1,625)	(488)	(4,910)	(975)	(2,833)
Loss after Finance cost		(4,917)	(1,789)	(48,990)	(8,269)	(68,489)
Taxation		-	-	-	-	(1,298)
Loss from Continuing Operation		(4,917)	(1,789)	(48,990)	(8,269)	(69,787)
Operation			-	-	-	-
Loss for the period		(4,917)	(1,789)	(48,990)	(8,269)	(69,787)
share):						
Profit per share-Kobo (Note: the number of shares as at Dec.'20, 217million shares. (See note 20 of Note to Account)		(2.3)	(0.8)	(22.6)	(3.8)	(32.16)

The financial statements and accompanying notes were approved by Board of Directors on

..... and signed on its behalf by:


G.A. Alegieund - DIRECTOR
(FRC/2014/ICAN/00000007613)


Funmilayo Adedeji - CHIEF ACCOUNTANT
(FRC/2020/ICAN/00000022389)

<i>Statements of Changes in Equity As At 30th June, 2022</i>					
Statement of Changes in Equity	Share Capital	Share Premium	Revaluation Reserve	Retained Earnings	Total
	N''000	N''000	N''000	N''000	N''000
Balance as at January 1, 2022	<u>108,466</u>	<u>380,009</u>	<u>1,756,588</u>	<u>(937,218)</u>	<u>1,307,845</u>
Total Comprehensive income of the Period					
Adjustment to opening Retained Earnings				-	
Loss for the year	-	-	-	(48,990)	(48,990)
Other comprehensive income	-	-	-	-	-
Total comprehensive income			-	(48,990)	(48,990)
Dividend paid	-	-	-	-	-
Unclaimed dividend written back	-	-	-	-	-
Total contributions by and distributions to owners of company recognised directly in equity.	-	-	-	-	-
Balance as at 30th June 2022	<u>108,466</u>	<u>380,009</u>	<u>1,756,588</u>	<u>(986,208)</u>	<u>1,258,855</u>
Balance as at January 1, 2021	<u>108,466</u>	<u>380,009</u>	<u>1,365,223</u>	<u>(867,431)</u>	<u>986,267</u>
Total Comprehensive income of the Period					
Loss for the year	-	-	-	(69,787)	(69,787)
Other comprehensive income			391,365		391,365
Total comprehensive income			391,365	(69,787)	321,578
Dividend paid	-	-	-		0
Unclaimed dividend written back	-	-	-		-
Total contributions by and distributions to owners of company recognised directly in equity.	-	-	-		-
Balance as at 31st Dec 2021	<u>108,466</u>	<u>380,009</u>	<u>1,756,588</u>	<u>(937,218)</u>	<u>1,307,845</u>

STATEMENT OF CASH FLOWS AS AT 30th June 2022			
STATEMENT OF CASH FLOWS AS AT 30th June 2022		AS AT June.'22	AS AT Dec.'21
	Note	N''000	N''000
Cash flows from operating activities			
Cash (used in)/generated from operations		(43,980)	(39,480)
Finance costs		(4,910)	(2,833)
Tax received (paid)	15	-	(1,164)
Net cash provided by operating activities		(48,890)	(43,477)
Cash flow from investing activities			
Purchase of property, plant and equipment		(207)	(26,066)
Purchase of intangible asset		-	-
Sales of PPE			225
Interest received and similar income	5.2	-	-
Net cash provided (used) by investing activities		(207)	(25,841)
Cash flow from financing activities			
Loans and borrowings	10.2	22,000	(336)
Repayment of borrowings			-
Dividend Paid	14	-	-
Net cash from financing activities		22,000	(336)
Total cash movement for the year		(27,097)	(69,654)
Cash at the beginning of the year		38,754	108,408
Effect of exchange rate movement on cash balances		-	0
Total cash at end of the period	10	11,657	38,754

Pharma Deko Plc
IFRS Financial Statements for January to June Ended 30th, 2022

Notes to the Financial Statement

1. Nature of Operations

The company's principal activities include the marketing, manufacturing of high quality pharmaceutical and consumer products. The consumer and pharmaceutical products share the same production utilities and the company leverages on this to ensure efficiency and effectiveness in its production process.

The company is also engaged in the canning of high quality beverages for other companies in the beverages – Brewers/distillers sector. Adequate investment is being made in this line to ensure that the company becomes the number one canning choice for beverages.

2. General information and statement of compliance with IFRS

The 2011 IFRS financial statements of the company have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

An explanation of how the transition to IFRSs has affected the reported financial position of the company is provided in the notes. The financial statement is presented in the functional currency, Nigerian Naira rounded up to the nearest thousand.

The 2011 IFRS financial statements have been approved by the Board of Directors in July 2012.

3. Summary of Significant Accounting Policies

3.1. Property, Plant and Equipment

Property, Plant and Equipment are tangible assets that can span more than one accounting period. These items are stated at their original cost or fair value less accumulated depreciation and impairment losses.

Land and Building is measured at fair value which is determined every two years. The fair value is determined by engaging the services of an external professional valuer.

Any increase as a result of the revaluation of Land and Building is recognized in other comprehensive income and accumulated in equity under the heading of revaluation surplus. However, the increase is recognized in profit or loss to the extent that it reverses a revaluation decrease previously recognized in profit or loss. If the revaluation results to a decrease in the carrying amount of Land and Building, the decrease is recognized in profit or loss. However, the decrease is recognized in other comprehensive income to the extent of any credit balance existing in the revaluation surplus in respect of the asset. Any revaluation surplus remaining in equity on disposal of the asset is transferred to retained earnings.

Plant and Machinery, Furniture and Fittings, Motor Vehicles and Computer Equipment are measured at cost.

The initial cost of these assets comprises its purchase price and any costs directly attributable to bringing the asset into operation.

The capitalized value of property, plant and machinery acquired via finance lease is also included within property, plant and equipment.

Pharma Deko Plc
IFRS Financial Statements for January to June Ended 30th, 2022

Notes to the Financial Statement (continued)

3.2 Depreciation and Impairment

Depreciation is charged over the estimated useful live of the assets when available for use and is calculated at the following rates per annum on cost or valuation:

	%
Buildings	2
Plant and Machinery	10
Furniture and Fittings	15
Motor Vehicles	20
Motor Bike/Tricycle	50
Computer Equipment	33 ¹ / ₃
Computer Software	33 ¹ / ₃

The useful lives and methods of depreciation of the assets are reviewed at each reporting period and adjusted prospectively if appropriate.

Impairment is measured as the difference between the carrying amount of an asset and its recoverable amount. Recoverable amount of an asset is the higher of its fair value less cost to sell and its value in use. Impairment is tested for when there is an indication of impairment such as:

- Decline in the market value of an asset;
- Changes in the technological, economic or legal environment resulting in an adverse effect on our activities;
- Obsolescence or damage of assets;
- Worsening performance of assets.

When there is an objective evidence of impairment, the loss is recognized in profit or loss except when there has been a previous upward revaluation in which case the impairment loss is recognized directly in equity.

Gains or losses arising on the disposal of property, plant and equipment are determined as the difference between the disposal proceeds and the carrying amount of the assets and are recognized in profit or loss within 'other income' or 'other expenses'.

3.3. Fair Value

Land and Building are measured at fair value by reference to market based evidence (Level 1 Fair Value Measurement). The fair value measurement is carried out every two years to ensure that the carrying amount of Land and Building is not materially different from its market value.

3.4. Lease Assets

In accordance with *IAS 17 Leases*, the economic ownership of a leased asset is transferred to the lessee if the

Lessee bears substantial all the risks and rewards related to the ownership of the leased asset. The related asset is then recognized at the inception of the lease at the fair value of the leased asset or, if lower, the present value of the lease payments plus incidental payments, if any. A corresponding amount is recognized as a finance leasing liability, irrespective of whether some of these lease payments are payable upfront at the date of inception of the lease.

Depreciation methods and useful lives of assets held under finance lease agreements correspond to those Applied to comparable assets which are owned by Pharma Deko PLC. The corresponding finance leasing

liability is reduced by lease payments less finance charges, which are expensed as part of finance costs.

Pharma Deko Plc
IFRS Financial Statements for January to June Ended 30th, 2022

Notes to the Financial Statement (continued)

The interest element of leasing payments represents a constant proportion of the capital balance outstanding and is charged to income statement over the period of the lease.

3.5. Inventories

Inventories are stated at the lower of cost and net realizable value after making adequate provision for obsolete, slow moving and damaged items. In case of good manufactured by the company, cost includes production overheads. Stock is valued at weighted average and goods in transit at the invoice price. Work in progress is stated at cost. Cost in this case consists of direct labour and materials plus appropriate proportion of factory overheads.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

3.6. Financial Instruments

a. Non Derivative Financial Assets

i. Trade Receivables

Trade receivables are financial assets measured at amortized cost less any impairment losses. Credit sales are rarely done and the effect of discounting is immaterial hence they are stated at their invoice price.

Trade receivables are assessed annually to determine if there is an objective evidence of impairment. The impairment loss is determined by splitting the receivables into groups of trade receivables that share similar credit risk characteristics. The credit risk groups are to be assessed for impairment using historical loss experience for each group. Such historical loss experience would be adjusted to reflect the effects of current conditions.

Staff Receivables, which are interest free and for a tenor of less than twelve months, is also measured at amortised cost. In this case it is the face value of the loan.

ii. Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand and demand deposits, together with other short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

b. Non-Derivative Financial Liabilities

The company has the following non-derivative financial liabilities: loans and borrowings, bank overdrafts, and trade and other payables.

Trade payables are measured at amortized cost. They are shown at face value because they do not carry any interest and usually have a tenor of two to three months.

Loans and Borrowings are recognized initially at fair value less any directly attributable transaction costs. Subsequently, they are measured at amortized cost using the effective interest method.

Pharma Deko Plc
IFRS Financial Statements for January to June Ended 30th, 2022

Notes to the Financial Statement (continued)

3.7. Taxation

Income tax and education tax payable are provided on taxable and assessable profits respectively at the current statutory rates.

Deferred Taxation

Deferred Taxation, which arises from timing differences in the recognition of items for accounting and tax purposes, is calculated using the liability method. Based on the IFRS provisions, IAS 12, liability method recognizes all timing differences as temporary differences. Temporary differences are differences between the tax base of an asset or liability and its carrying amount in the statement of financial position. The tax base of an asset or liability is the amount attributed to that asset or liability for tax purposes. The measurement of deferred tax liabilities and deferred tax assets shall reflect the tax consequences that would follow from the manner in which Pharma Deko Plc expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Deferred income tax assets and liabilities are measured at the rates that are expected to apply to the year when the asset is realized or the liability settled, based on tax rates (and tax laws) that have been enacted at the Statement of Financial Position date. Deferred tax assets are recognized when it is considered probable (more likely than not) that those assets will be recovered.

3.8. Foreign Currency Transaction

Transactions denominated in foreign currencies are translated into Naira at the ruling rates of exchange at the date of transaction. Monetary assets and liabilities denominated in foreign currencies are reported at the prevailing exchange rate at the balance sheet date. Any gain or loss arising from a change in exchange rates is charged to the Statement of Profit or Loss and Other Comprehensive Income.

3.9. Employee Benefits

The company provides a contributory pension fund scheme which is funded by contributions from employees at 8% and employer at 10% based on basic salary, housing and transport in line with the Pension Reform Act of 2014. The employers' contribution is charged to the statement of profit or loss and comprehensive income. Contributions are expensed in the period they are payable and any unpaid contribution at the end of the period are recognised as a liability.

The company also operates an unfunded retirement benefit scheme. The benefits are based on the employers' year of service and terminal salary. They are yet to be measured in accordance with *IAS 19 Employee Benefits*.

3.10. Provisions

Provisions are recognized when the company has a present obligation, whether legal or constructive, as a result of past events for which it is probable that an outflow of resources embodying economic benefits will be

required to settle the obligation and a reliable estimate can be made of the amount of the obligation in accordance with IAS 37 *Provisions, contingent liabilities and contingent assets*.

3.11. Operating Segments

An operating segment is a component of the company that engages in business activities from which it may earn revenues and incur expenses. All operating segment operating results are reviewed from time to time by the management of the company to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.

Pharma Deko Plc

IFRS Financial Statements for January to June Ended 30th, 2022

Notes to the Financial Statement (continued)

Segment results that are reported to the CEO include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise all assets, liabilities and income tax assets and liabilities.

3.12. Revenue

Sales of Goods

The sales of good comprise of pharmaceutical goods and consumer goods. Revenue from the sale of these Goods in the course of ordinary activities are measured at the fair value of the consideration received or receivable, net of returns, trade discounts, sales tax and volume rebates. Revenue is recognized when the Risks and rewards of ownership are transferred to the buyer. This occurs when the buyer has taken delivery of the goods. Revenue is recognized when the amount of revenue can be measured reliably, the collection is probable and the costs incurred or to be incurred can be measured reliably.

Rendering of Services

The rendering of services involves the canning of consumer beverages. Revenue is recognized when the The amount of revenue can be measured reliably, the collection is probable, costs incurred and cost to complete can be measured reliably and stage of completion can be ascertained at the end of the reporting period. The stage of completion is determined by using the surveys of work completed.

3.13. Discontinued Operations

A discontinued operation represents a component of the company's principal business that is a separate major line of business or geographical area of operations that has been disposed of or is held for sale. Classification as a discontinued operation occurs upon disposal or when the operation meets the criteria to be classified as held for sale, if earlier.

Profit or loss from discontinued operations is presented in a single amount in the income statement. This amount is the post-tax profit or loss of discontinued operations.

3.14. Earnings per Share

The company presents basic earnings per share (EPS) data for its ordinary shares. The Basic EPS is determined by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period.

3.15. Investment Properties

Investment properties are properties held either to earn rental income or for capital appreciation or for both, but not for sale in the ordinary course of business, use in the production or supply of goods or services or for

administrative purposes.

Though the company collects rent from a portion of its warehouse, it is not considered an investment property because the portion used for production or supply of goods and services is significant compared to the portion used for rent.

Pharma Deko Plc

IFRS Financial Statements for January to June Ended 30th, 2022

Notes to the Financial Statement (continued)

3.16. Significant Management Judgment in applying Accounting Policies and Estimation Uncertainty

When preparing the financial statements, management undertakes a number of judgments, estimates and assumptions about the recognition and measurement of assets, liabilities, income and expenses.

Below is the significant management judgment in applying the accounting policies of Pharma Deko PLC that has the most significant effect on the financial statements.

Taxation on Discontinued Operations

IFRS 5 requires that the post-tax profit/(loss) of discontinued operations be shown as a single line item the Statement of Profit or Loss and Other Comprehensive Income.

However, in these financial statements, the result of the discontinued operations is shown as the pre-tax loss.

This is because of the complexity of separating assets and liabilities of the discontinued operations from the entire continuing operations of the company. This has prompted management to exercise significant judgment to disclose the result of discontinued operations on a pre-tax basis.

4. Revenue by business segment

Business	6 months	6 months	12 months
	2022	2021	2021
	N'000	N'000	N'000
Pharma	73,220	81,586	168,031
Consumer	179,590	230,147	335,517
TOTAL	252,810	311,733	503,548

5a. Operating Segment

Pharma Deko Plc is engaged in the manufacturing and marketing of high quality pharmaceutical and marketing products. The company has three reportable segments which serve as the company's strategic business units. These operating segments are assessed and strategic decisions are made on the basis of operating segment results. The following summary describes the operations in each of the reportable segments:

Pharma: This refers to the pharmaceutical products of the company;

Consumer: This refers to non alcoholic drink products of the company (Sans cream soda).

Contract: This refers to the bottling & canning of beverages for other companies.

Due to the nature of the company's operations and the relationship among the above segments (sharing of production lines), the assets and the liabilities of the company cannot be determined on a segmental basis and does not form part of the information provided to management for segmental review. Hence, such information is not disclosed as part of operating segments.

Pharma Deko Plc

IFRS Financial Statements for January to June Ended 30th, 2022

Notes to the Financial Statement (continued)

5.1 Summary of operating segments

Also, Cost of Sales, Selling and Distribution Costs, Administrative Expenses and Interest Expenses are Distributed evenly to all segments due to the reason mentioned above.

Summary of Operating Segment-Jan- June '22	Pharma	Consumer	Total
	N'000	N'000	N'000
Segment Revenue	73,220	179,590	252,810
Cost of Good Sold	(50,020)	(128,160)	(178,180)
Depreciation	(8,700)	(20,300)	(29,000)
Total Cost of sales	(58,720)	(148,460)	(207,180)
Selling and Distr.	(14,260)	(7,910)	(22,170)
Admin. Exp.	(28,050)	(65,460)	(93,510)
Interest Exp.	(4,380)	(530)	(4,910)
	(105,410)	(222,360)	(327,770)
Segment Profit after Extra-Ordinary	(32,190)	(42,770)	(74,960)
Summary of Operating Segment-Jan-June.'21	Pharma	Consumer	Total
	N'000	N'000	N'000
Segment Revenue	81,586	230,147	311,733
Cost of Good Sold	(58,719)	(125,344)	(184,062)
Depreciation	(9,832)	(22,942)	(32,775)
Total Cost of sales	(68,551)	(148,286)	(216,837)
Selling and Distr.	(9,600)	(12,309)	(21,909)
Admin. Exp.	(25,962)	(60,579)	(86,541)
Interest Exp.	(975)	0.0	(975)
	(105,088)	(221,174)	(326,262)
Segment Profit after Extra-Ordinary	(23,502)	8,973	(14,529)

5.2 Reconciliation of operating segment profit before other income		
Description	Jan- June'22	Jan-June'21
	N'000	N'000
Total Profit for Segments	(74,960)	(14,529)
Discontinued Operations	-	-
	(74,960)	(14,529)
Add: Unallocated Amount		
Other operating Income	25,970	6,260
Company Profit before Income Tax	(48,990)	(8,269)
Details of Other Income	N'000	N'000
Foreign Exchange Gain	-	109
Write-back of provision		
Miscellaneous Income		643
Interest Income & Similar		
Sales os scrap	25,970	5,508
Net Arbitration Award		-
	25,970	6,260

Other Income represents exchange gain on FX , Insurance claim and sales from used kegs, drums, caps and nylons.

Note of Account.									
AS AT JUNE 2022 ENDING.									
PROPERTY, PLANT AND EQUIPMENT									
	Note	Land	Building	Plant and	Furniture and	Motor	Computer	Fixed Asset	
	6	Land	Building	Machinery	Fittings	Vehicles	Equipment	in Progress	Total
		N''000	N''000	N''000	N''000	N''000	N''000	N''000	N''000
<u>COST/VALUATION</u>									
At 1 January 2022		794,135	748,845	623,465	11,917	116,683	32,584	115,389	2,443,018
Assets Movement		-	-	42,286	-	-	-	(42,286)	-
Additions		-	-	-	-	-	207	-	207
At 30th June' 2022		794,135	748,845	665,751	11,917	116,683	32,791	73,103	2,443,225
Accumulated Depreciation									
At 1st January 2022		-	39,472	227,686	8,539	98,663	12,187	-	386,546
Charge for the period		-	7,094	21,904	254	1,802	3,400		34,454
At 30th June' 2022		-	46,566	249,590	8,793	100,465	15,587	-	421,000
Impairment									
At 1st January 2022		-	-	-	-	-	-	-	-
Impairment on revalued		-	-	-	-	-	-	-	-
Assets written back		-	-	-	-	-	-	-	-
Charge for the period		-	-	-	-	-	-		-
At 30th June' 2022		-	-	-	-	-	-	-	-
Net book value									
At 30th June' 2022		794,135	702,279	416,161	3,124	16,218	17,204	73,103	2,022,225
At 31st Dec 2021		794,135	709,373	395,779	3,378	18,020	20,397	115,389	2,056,472
	Note	Land	Building	Plant and	Furniture and	Motor	Computer	Fixed Asset	
	6.1	Land	Building	Machinery	Fittings	Vehicles	Equipment	in Progress	Total
		N''000	N''000	N''000	N''000	N''000	N''000	N''000	N''000
<u>COST/VALUATION</u>									
At 1st July 2021		606,160	655,364	614,639	10,310	98,761	13,006	76,870	2,075,110
Assets Movement (Disposal)		-	-	(204)	-	-	-	-	(204)
Additions		-	-	12,992	-	-	-	-	12,992
Revaluation Surplus (Deficit)		187,975	93,481	(3,962)	1,607	17,922	19,578	38,519	355,120
At 31st Dec 2021		794,135	748,845	623,465	11,917	116,683	32,584	115,389	2,443,018
Accumulated Depreciation									
At 1st July 2021		-	32,919	201,014	7,940	98,394	11,987	-	352,254
Charge for the period		-	6,553	26,672	599	269	200	-	34,293
At 31st Dec 2021		-	39,472	227,686	8,539	98,663	12,187	-	386,546
Impairment									
At 1st July 2021		-	-	-	-	-	-	-	-
Impairment on revalued		-	-	-	-	-	-	-	-
Assets written back		-	-	-	-	-	-	-	-
Charge for the period		-	-	-	-	-	-		-
At 31st Dec 2021		-	-	-	-	-	-	-	-
Net book value									
At 31st Dec 2021		794,135	709,373	395,779	3,378	18,020	20,397	115,389	2,056,472
At 30th June' 2021		606,160	655,364	614,639	10,310	98,761	13,006	76,870	2,075,110

	Note	As At June'2022	AS AT Dec '2021
INVENTORY	7	N''000	N''000
Raw material		31,957	69,760
Work in Progress		4,133	4,896
Finished goods		50,037	23,272
Packaging Material		44,319	59,763
Engineering Consumable Item./Diesel		21,971	24,692
		152,417	182,383
Impaired inventories	7.1	-	-
		152,417	182,383
	Note	As At June'2022	AS AT Dec.'2021
TRADE RECEIVABLES	8	N''000	N''000
Trade Receivables		46,747	11,690
Impairment of trade receivables		-	-
		46,747	11,690
<i>Trade Receivables are non-interest bearing and are generally on a 30 day term</i>			
	Note	As At June'2022	AS AT Dec.'2021
OTHER RECEIVABLES AND PREPAYMENTS	9	N''000	N''000
Staff debtors		-	
Cash Advance		810	97
Total Finance Assets		810	97
Sundry Receivables(Reclassification)		-	19,403
Prepayments		447	-
Deposit for import-PPE & MAT.		27,760	26,522
Prepaid Housing Allowance		-	-
Total Non Finance Assets		28,207	45,925
		29,017	46,022

	Note	As At June'2022	AS AT Dec.'2021
CASH AND CASH EQUIVALENTS	10	N''000	N''000
Cash at Bank		11,657	38,656
Cash in hand			98
Cash and cash Equivalents		11,657	38,754
Bank overdrafts used for cash management pu	10.1	-	
Bank overdrafts			-
Cash and cash Equivalents in Statement of CFs.		11,657	38,754
Loans and Borrowings-Current Financial Liabilities			
	Note	As At June'2022	AS AT Dec.'2021
	10.2	N''000	N''000
Loan & Bank overdrafts		10,000	-
Promissory note		25,000	13,000
		35,000	13,000
Employment Benefits-Gratuity	Note	As At June'2022	AS AT Dec.'2021
	11	N''000	N''000
At 1. January		197,827	200,261
Charge for the year		-	-
Payment during the year		(250)	(2,434)
		197,577	197,827
Trade Payables-Current Financial Liabilities	Note	As At June'2022	AS AT Dec.'2021
	12	N''000	N''000
Trade Payable		13,509	14,584
		13,509	14,584

Other Payables	Note	As At June'2022	AS AT Dec.'2021
Financial Liability	13.1	N''000	N''000
Sundry creditors (Note 13.3)		209,255	249,459
Accruals		167,424	164,572
Vat-payable		30,119	43,002
Employee Benefits-Unpaid Contr. (Note 13.4)		164,032	158,740
		570,830	615,773
Non Financial Liability	13.2		
Deferred Rent Income		-	-
Customer's deposit		-	-
		-	-
Total		570,830	615,773
Sundry creditors	Note	As At June'2022	AS AT Dec.'2021
	13.3	N''000	N''000
Other creditors		368	43,935
Industrial training fund		20,876	20,160
Union Dues		4,383	4,117
Withholding Tax on Dividend		370	231
Withholding Tax on Services		49,442	48,090
Pay As You Earn (PAYE)		9,761	7,901
Salaries and Wages Payable		99,754	96,540
1% NSITF		19,445	18,729
Dividend Payable (Note 14.1)		4,856	4,856
Working Capital Loan		-	4,900
		209,255	249,459
Employee Benefits-Unremitted Contributor	Note	As At June'2022	AS AT Dec.'2021
	13.4	N''000	N''000
At January		158,740	153,303
Charge for the year		5,292	9,869
Remittances during the year		-	(4,432)
At 30 June' 2022		164,032	158,740

Dividend Paid	Note	As At June'2022	AS AT Dec.'2021
	14	N''000	N''000
Dividends		-	
Dividend Payable	Note	As At June'2022	AS AT Dec.'2021
	14.1	N''000	N''000
At January 1		4,856	4,856
Returned dividend		-	-
Unclaimed dividend transferred to retained income		-	-
		4,856	4,856

Tax Charge for the Year	Note				
	15				
		Company tax	Education Tax	Capital gain tax	Total
At January 1		24,776	44	99,916	124,736
Charge for the year (minimum tax)		-	-	-	-
Payments		-	-	-	-
At 30 June.' 2022		24,776	44	99,916	124,736
Deferred tax liability	Note	As At June'2022	AS AT Dec.'2021		
	16	N''000	N''000		
At beginning of year		61,556	61,556		
Charge for the year		-	-		
Capital gains tax		-			
		61,556	61,556		

	Note	As At June'2022	AS AT Dec.'2021
Share Capital Authorised	17	N''000	N''000
300,000,000 ordinary shares of 50k each		<u>150,000</u>	<u>150,000</u>
Ordinary Shares Issued and Fully Paid			
At 1 January		108,466	108,466
Movement during the year		<u>-</u>	<u>-</u>
		<u>108,466</u>	<u>108,466</u>
Number of Ordinary Shares		No in thousand	No in thousand
At 1 January		216,932	216,932
Movement during the year		<u>-</u>	<u>-</u>
		<u>216,932</u>	<u>216,932</u>
	Note	As At June 2022	AS AT Dec.'2021
Share Premium	18	N''000	N''000
At 1 January		380,009	380,009
Movement during the year		<u>-</u>	<u>-</u>
		<u>380,009</u>	<u>380,009</u>
	Note	As At June 2022	AS AT Dec.'2021
Revaluation Reserve	19	N''000	N''000
At 1 January		1,756,588	1,756,588
Movement during the year		<u>-</u>	<u>-</u>
		<u>1,756,588</u>	<u>1,756,588</u>

	Note	As At June 2022	AS AT Dec.'2021
Retained Earning	20	N''000	N''000
Revenue reserves		(937,218)	(867,431)
Dividend Paid		0	0
Unclaimed dividend written back		0	0
(Loss)/Profit for the period		(48,990)	(69,787)
		(986,208)	(937,218)
Basic Earnings Per Share		As At June 2022	AS AT Dec.'2021
Earnings/(loss) per share from continued Operation (kobo)		(22.6)	(32.2)
		(22.6)	(32.2)
Basic Earnings per Share			
The calculation of basic earnings per share was based on the Profit for the period and average number of ordinary shares outstanding of 216,932 thousand.			
		Continued Operations	discontinued Operations
		N'000	N'000
(Loss)/Profit as at 30 June 2022		(48,990)	-
(Loss)/Profit as at 30 June 2021		(8,269)	-
Weighted Average Number of Shares			

Reconciliation of Profit before Taxation to Net Cash provided by Operating Activities			
	Note	As At June 2022	AS AT Dec.'2021
	21	N''000	N''000
Loss before taxation		(48,990)	(68,489)
Adjustments to reconcile net loss to net cash provided by operating activities:			
Depreciation & amortisation		34,454	67,880
Profit on Disposal of Asset		-	21
Gains on foreign exchange		-	-
Finance cost		4,910	2,833
Movements in retirement benefit assets and liabilities		(250)	(2,434)
Changes in working capital:			
Inventories		29,966	(8,281)
Trade receivables		(35,057)	8,741
Other Receivable		17,005	-
Trade payable		(1,075)	(47,269)
Other payables		(44,943)	7,518
		5,010	29,009
Cash provided by operating activities.		(43,980)	(39,480)